NCT00005613View on ClinicalTrials.gov

Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

March 31, 1996

Primary Completion Date

October 31, 2006

Study Completion Date

June 30, 2010

Conditions
Lymphoma
Interventions
DRUG

cyclophosphamide

Cyclophosphamide will be given at a dose of 1500 mg/m2/day IV over 1.0 hour on days -6, -5, -4, and -3.

DRUG

etoposide

Etoposide will be given at a dose of 600 mg/m2/day over 3.0 hours on days -6, -5, and -4.

DRUG

BCNU

BCNU will be given at a dose of 150 mg/m2/day in 500 cc D5W over 3.0 hours on days -6, -5, and -4

Trial Locations (2)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

33901

Florida Cancer Specialists, Fort Myers

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT00005613 - Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | Biotech Hunter | Biotech Hunter